Objective. Identification of the association of killer cell immunoglobulin-like receptor (KIR) genes with SLE and accompanying infections.
Introduction
Killer cell immunoglobulin-like receptors (KIRs) belong to the immunoglobulin superfamily, and are expressed on both NK cells and subsets of T cells [1] . KIRs comprise a diverse receptor family that consists of 14 distinct genes. KIRs contain either two (2D) or three (3D) Ig-like domains in the extracellular domains and either long (L) or short (S) cytoplasmic tails. Long-tailed receptors carry one or two immunoreceptor tyrosine-based inhibititory motifs (ITIMs) that contribute to inhibitory signalling. Short-tailed receptors have a lysine residue in their transmembrane domain that is required for pairing with the immunoreceptor tyrosine-based activation motifs-containing adaptor DAP12 [1] . KIRs specifically recognize MHC Class I molecules on target cells and transmit either stimulatory or inhibitory signals, depending on the sequence of their intracellular domain, into KIR-bearing cells [2, 3] .
HLA-KIR gene interactions have been shown to be involved in disease outcome for a number of viral infections [4, 5] . In addition to an important role in innate immunity, the involvement of NK cells in autoimmunity has also been suggested. Furthermore, defects in NK function have also been demonstrated in animal models of autoimmune diseases [6, 7] . Recent genetic studies have demonstrated an association between KIR and the onset of autoimmune diseases, such as RA and scleroderma [8] [9] [10] [11] .
SLE is a systemic autoimmune disorder characterized by the production of a broad variety of autoantibodies and subsequent immune complex deposition, which results in chronic inflammation in multiple organ systems. Although the pathogenesis of SLE is still not clarified, substantial contribution of genetic factors has been implicated [12] [13] [14] [15] [16] . While T-cell and/or B-cell dysfunction have been implicated in the pathogenesis of SLE [17] [18] [19] , the involvement of NK cells has not been clarified. The aim of this study was to clarify the involvement of NK cells in the pathogenesis of SLE.
In the present study, we genotyped all known 14 KIRs in 417 SLE patients and 72 RA patients, and association with these diseases was analysed by case-control studies. In addition, the association between KIRs and infection was analysed in 184 SLE patients whose medical records are available. Our study revealed that individuals carrying KIR2DL5, which is supposed to transmit inhibitory signals for NK cells, are at a decreased risk of SLE as well as an increased risk of infection.
Patients and methods

Patients
We studied a total of 417 SLE patients and 72 RA patients who were followed up at the Rheumatology Clinic of Kyushu University Hospital and its affiliated hospitals. All SLE patients fulfilled the ACR 1997 revised criteria for SLE [20, 21] . RA patients fulfilled the ACR 1987 criteria [22] . A total of 256 healthy nursing college students were enrolled in the association study. All individuals were Japanese. The study was approved by our institutional review board and all participants provided written informed consent.
For analysis of the relationship between KIR genotype and clinical manifestation, patients who were hospitalized at Kyushu University Hospital from 1996 to 2004 were eligible for inclusion. In total, the medical records of 184 Japanese patients with SLE were included. Infectious events were identified within the medical records of enrolled patients separately for bacterial, viral, fungal and mycobacterial infection.
A major infection of bacteria, fungus or mycobacteria is defined as a microbiologically confirmed infection that needed antimicrobial treatment and admission [23] .
The diagnosis of a major bacterial or fungal infection required compatible clinical or radiological findings and/or the identification of a causative organism from sputum, nasopharyngeal aspirates, bronchoalveolar lavage, blood, urine or spinal fluid. Cases that required antibiotic or antifungal treatment were enrolled. Superficial fungal infection (e.g. skin and gastrointestinal) was not included as a major fungal infection. The definition of viral infection is as follows: episodes of infection caused by CMV were included, if positive CMV antigenaemia or culture results were deemed clinically significant and treatment was administered. All herpes zoster, varicella zoster and the reactivation of HSV or varicella zoster virus (VZV) cases were confirmed using fluorescent antibody for HSV-1, HSV-2 and VZV. Severe viral infection was confirmed by alteration of antibody value between paired sera. Other viral infections were estimated from the patient's clinical manifestation, clinical course and negative culture results for microbes considered as possible causes. A diagnosis of mycobacterial infection required compatible clinical or radiological findings and/ or identification of mycobacteria from the culture of sputum, bronchoalveolar lavage and/or a PCR of mycobacterial genome DNA.
KIR typing
Total genomic DNA was isolated from blood samples using Qiagen QIAamp DNA blood Maxi Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol [13] .
Genotyping of KIR locus was performed to detect the presence or absence of 14 KIR loci (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3 and KIR3DS1) using sequence-specific primer-PCR with minor modifications [24] . Briefly, PCR was performed in 10-ml reaction mixtures containing 100 ng of genomic DNA, 0.1-2.5 mM of each primer, 0.2 mM deoxyribonucleotide triphosphate, 1.5 mM MgCl 2 and 0.5 U of ExTaq DNA polymerase (Takara, Otsu, Japan), using a GeneAmp PCR System 9700 Thermocycler (Applied Biosystems, Foster City, CA, USA).
The PCR conditions were as follows: initial denaturation at 95 C for 2 min; 10 cycles of denaturation at 94 C for 20 s; annealing at 65 C for 10 s; and extension at 72 C for 90 s; followed by 20 cycles of denaturation at 94 C for 20 s; annealing at 61 C for 20 s; and extension at 72 C for 90 s, then a final extension step at 72 C for 10 min. The PCR products were electrophorized using a 1.2% agarose gel. Examination of the gel using an ultraviolet transilluminator determined the presence or absence of each KIR gene.
Statistical analysis
Comparisons of means, proportions and medians were based on unpaired t-test, 2 -test and Wilcoxon ranksum test, respectively. Fisher's exact test was performed, in addition to 2 , for 2 Â 2 tables, when the table has a cell with an expected frequency of <5. Unconditional logistic www.rheumatology.oxfordjournals.org regression was used to compute the odds ratios (ORs) and their 95% CIs, with adjustments for several covariates found to be associated with SLE risk (age, sex, smoking status and education).
All statistical analyses were performed using the computer program STATA Version 8.2 (STATA Corporation, College Station, TX, USA). All P-values were two-sided, with those <0.05 considered statistically significant.
Results
Frequency of KIR loci in SLE patients and controls
We first analysed DNA samples from 47 SLE patients and 48 randomly selected healthy controls from the study population, with the exception of KIR2DL2 and KIR2DS2. As these two genes have been shown to be associated with a number of autoimmune diseases [8, 9, 25, 26] , about twice the number of patients and controls were employed. The carrier frequency of each KIR locus among patients with SLE and healthy individuals is shown in Table 1 . Only the frequency of KIR2DL5 in SLE patients tended to be decreased compared with that of healthy individuals (34.0 vs 47.9%; P = 0.102), whereas those of the other KIRs were not significantly different between SLE patients and healthy individuals.
In order to validate the association between KIR2DL5 and SLE, additional DNA samples were enrolled in the study. A total of 417 SLE patients and 256 healthy controls were analysed ( Table 1 ). The carrier frequency of KIR2DL5 was significantly decreased in patients with SLE as compared with healthy controls (39.3 vs 50.4%, P = 0.005; OR = 0.64; 95% CI 0.36, 0.92). For 72 RA patients, the frequency of KIR2DL5 was 44.4%, which was not significantly different from healthy controls or SLE patients ( Table 1) . As for other KIRs, all but one, KIR2DS1, was not significantly different between SLE patients and healthy individuals. The frequency of KIR2DS1 was 58.3% in RA patients, which was significantly increased compared with that in healthy controls and SLE patients (P = 0.04).
Clinical features of SLE patients with or without KIR2DL5
We studied clinical features of 184 SLE patients whose medical records were available and obtained data concerning the presence or absence of their infectious events. Of 184 SLE patients, 78 were carrying KIR2DL5 [KIR2DL5 (+)] and 106 were not [KIR2DL5 (À)]. In 6 out of the 184 patients, the clinical data of interest were not completely described. The data of the remaining 178 patients are as follows: the average age at disease onset was 31.1 years for KIR2DL5 carriers and 28.0 years for non-carriers. This difference was not statistically significant. The presence or absence of nephritis, ANA, anti-dsDNA antibody and anti-Sm antibody was not significantly different between KIR2DL5 (+) and KIR2DL5 (À) SLE patients.
However, the incidence of CNS involvement was 30.1% in KIR2DL5 (+) individuals (22 of 73) and 14.3% in KIR2DL5 (À) individuals (15 of 105); this difference was statistically significant (P = 0.0104). The incidence of thrombocytopenia was 52.1% in KIR2DL5 (+) individuals (38 of 73) and 31.4% in KIR2DL5 (À) individuals (33 of 105); this difference was also statistically significant (P = 0.0057).
KIR loci and infection in SLE patients
NK cells play a role in the elimination of tumour cells and virus-infected cells. Therefore, it is possible that the presence or absence of KIR affects the risk of infection for SLE patients, who are often prescribed corticosteroids and immunosuppressive agents. We examined whether the presence or absence of each KIR was associated with infection susceptibility.
An episode of major infection occurred in 184 SLE patients during hospitalization for the treatment of onset or flare-ups of SLE. Two patients died due to infection during the observation period: one due to pneumococcal pneumonia and the other due to non-tuberculous mycobacterial infection. Both cases were carrying the KIR2DL5 locus.
When the association between the infectious events and the genotypes of the 14 KIRs was analysed, the presence of KIR2DL5 was significantly associated with the overall frequency of infectious and viral infectious events As KIR2DL2 and KIR2DS2 have been shown to be associated with autoimmune diseases [8, 9, 25, 26] , the numbers of samples studied are almost double (KIR2DL2, n = 95 for SLE patients and n = 92 for controls; KIR2DS2, n = 96 for SLE patients and n = 95 for controls) compared with those for other KIRs; *P = 0.102, compared with SLE patients, **P = 0.04, compared with SLE patients and controls, ***P = 0.005, compared with SLE patients.
( Table 2 ). Out of 184 SLE patients, a total of 22 major episodes of bacterial infection were observed: three cases of sepsis; two cases of infectious endocarditis; three cases of nocardiosis; and one case each of empyema, pulmonary suppuration, abdominal wall abscess and pneumococcal pneumonia. A total of 43 major viral infections were identified: 24 cases of herpes zoster; 4 cases of CMV infection; 3 cases of CMV antigenaemia; 3 cases of varicella zoster; 1 case of rhabdomyolysis due to Coxsackie B2; and 1 case each of myocarditis, aseptic meningitis, measles encephalitis and infectious mononucleosis. Three cases of major fungal infections (two cases of invasive pulmonary aspergillosis and one case of pulmonary cryptococcosis) and eight cases of mycobacterial infection (seven cases of pulmonary tuberculosis and one case of non-tuberculous mycobacterial infection) were observed.
There have been a large number of reports concerning factors for predisposition to infection in SLE patients. In particular, corticosteroids and immunosuppressive agents have been found to be significantly associated with infection [27, 28] . We therefore examined the prevalence of infectious events according to whether the patients had received methylprednisolone (mPSL) pulse and/or cyclophosphamide pulse (IVCY) therapy (Table 3) . In patients treated with mPSL pulse, the prevalence of overall infectious events was 55.9% (19 of 34), whereas that without mPSL pulse therapy was 30.6% (37 of 121), which was significantly different (P = 0.0067; OR = 2.88; 95% CI 1.32, 6.27). The prevalence of viral infectious events was 38.2% (13 of 34) in the group with mPSL pulse therapy and 19.0% (23 of121) in the group without mPSL pulse therapy, which was also significantly different (P = 0.019; OR = 2.63; 95% CI 1.15, 6.03). However, no statistically significant difference was observed for the frequency of bacterial, fungal or mycobacterial infection. In the patients treated with IVCY therapy, there was no statistically Association between KIR2DL5 or mPSL and infectious events in SLE patients is shown in Table 4 . The impact of infection in SLE patients carrying KIR2DL5 was comparable with that of SLE patients treated with mPSL pulse therapy. mPSL pulse therapy was at risk of overall or viral infectious event. KIR2DL5 (+) was significantly associated with overall infectious events (adjusted OR = 2.45; 95% CI 1.24, 4.81; P = 0.0095) while KIR2DL5 (+) was marginally associated with an increased risk of viral infection in SLE patients (adjusted OR = 2.03; 95% CI 0.94, 4.41; P = 0.0718).
Discussion
We report here that an inhibitory KIR molecule for NK cells, KIR2DL5, is associated with a decreased risk of SLE as well as an increased risk of infection, in a cohort of Japanese patients with SLE. Expression of KIR2DL5 has been detected in subpopulations of NK cells and T cells, both at the transcription level [29] and at the protein level [30] . KIR2DL5 has two ITIMs in its cytoplasmic region and is thus assumed to transmit inhibitory signals in NK cells [31] . Although the ligand of KIR2DL5 is still undetermined, KIR2DL5 is considered to be one of the functional inhibitory receptors [30] .
Specific activating KIRs have been implicated in having an association with the onset of autoimmune diseases. In particular, KIR2DS2 was shown to be associated with the development of rheumatoid vasculitis, probably due to its expression on CD4 + CD28 À T cells [8] . This subset of T cells can be activated directly through KIR2DS2 without the need for conventional TCR stimulation by antigenic peptide [32] . The presence of KIR2DS2 in the absence of KIR2DL2 was associated with scleroderma [9] . In addition, KIR2DS1 and/or KIR2DS2 have been reported for the association of development of PsA [25] . In Caucasian SLE patients, an increased frequency of KIR2DS1 in the absence of KIR2DS2 has been reported [33] .
However, there were a number of limitations in previous studies. First, a number of KIRs including KIR2DL5 were missing from the analyses in these studies. Secondly, no correction was made for multiple testing. In the present study, we screened all KIRs for association with SLE and finally identified a protective effect of KIR2DL5 for SLE. The incidence of inhibitory KIR2DL5 in SLE patients in our study (39.3%) was significantly decreased compared with that of healthy controls (50.4%). Lack of association between KIR2DL5 and RA further supports the specific involvement of KIR2DL5 in SLE.
NK cells are supposed to be involved in the initiation of autoimmunity, either by direct cytotoxic effect against self tissues or by indirect modulation of autoreactive T cells [34] . Following induction of autoimmunity, NK cells are primed and proliferate, which leads to induction of autoreactive T cells [35] . After autoreactive T cells have been activated, NK cells are then suppressed and degenerated [36] . In accordance with this hypothesis, in SLE patients whose autoreactive T cells are already induced, circulating levels of NK cells are diminished and their cytotoxicities are impaired. Inhibitory receptor KIR2DL5, may play a protective role in the initiation of SLE by suppressing NK-cell cytotoxicity. In consistence with this hypothesis, KIR2DL5 was less frequent in SLE patients compared with healthy controls (Table 1) . Another possibility for the inverse association of KIR2DL5 and SLE is that the KIR2DL5 gene is in linkage disequilibrium with a region carrying a defect responsible for the pathogenesis of SLE.
In addition to NK cells, a subset of T cells expressing these particular KIR molecules might be actively involved in the inflammatory response as in the case of CD4 + CD28
À T cells in RA [37] [38] [39] . In particular, a stimulatory NK receptor, KIR2DS2, located on CD4 + CD28 À T cells transduces an activation signal and functions as a co-stimulatory signal involved in the pathogenesis of autoimmune diseases such as RA [32] . In our SLE patients, we found that CD4 + CD28
À T cells were increased as was the expression of KIR2DL5 in this subpopulation of T cells (data not shown). Considering such Pulse therapy includes both mPSL pulse and cyclophosphamide pulse therapy. *P = 0.007, compared with no history of therapy, **P = 0.019, compared with no history of therapy.
results, there is a possibility that KIR2DL5 may play a role in the activity of T cells. The reason why CNS involvement and thrombocytopenia are more frequent in SLE patients carrying KIR2DL5 is not clear. The function of KIR2DL5 is not well characterized; however, it is possible that KIR2DL5 may modulate cytokine production, regulate the function of T cells and dendritic cells and the recruitment of NK cells to target organs. In the development of SLE, after the initiation of autoimmune response, KIR2DL5 may be involved in the phenotype of the patients.
In addition, an increased prevalence of infection was associated with KIR2DL5 status in our SLE patients. A number of KIR genes have been reported to be associated with infectious diseases [40] . Among these genes is included the compound genotype KIR3DS1 and a subset of HLA-Bw4 + for protection against HIV, as well as KIR2DL3 in combination with HLA-C Asn80 for protection against HCV [5]. In our 184 SLE patients, whose medical records were available, the risk of overall infections and viral infections was significantly increased in KIR2DL5 carriers compared with non-carriers ( Table 2) . The risk for infection in KIR2DL5 (À) carrying patients was comparable with that in mPSL pulse-treated patients (Table 3) . After adjusting for confounding factors, the risk of overall infections for KIR2DL5 carriers was significantly increased (adjusted OR = 2.45; 95% CI 1.24, 4.81; P = 0.0095; Table 4 ). Although controversial, deficiency of mannose-binding lectin (MBL) is also considered to be one of many genetic factors for serious infection in SLE patients who are also treated with immunosuppressive agents [41] [42] [43] . MBL activates the complement cascade independently of antibodies and is supposed to act as the most proximal and important component of innate immunity of host defence. Also controversial is that the deficiency of MBL is suggested to be a risk factor for developing SLE [23, 44] . It is, therefore, considered that MBL is involved both in the risk for SLE and in complicating infections such as in the case of KIR2DL5.
In the present study, we have presented evidence that inhibitory KIR2DL5 is associated with a decreased risk of SLE and an increased risk of infection in SLE patients. It is, therefore, suggested that NK-cell function may be critical for the pathogenesis of SLE as well as for protection against accompanying infections. Our data support a role for KIR in disease susceptibility in autoimmune diseases and infections.
Rheumatology key messages
. KIR2DL5 was significantly associated with a decreased risk of SLE. . An increased risk of overall infectious events was observed in SLE patients carrying KIR2DL5. 
